Press release content from PR Newswire. The AP news staff was not involved in its creation.
Eurofins Transplant Diagnostics Group Receives New York State CLEP Approval for Novel Rejection Biomarker Assays
April 27, 2021 GMT
Eurofins Transplant Diagnostics
LEE’S SUMMIT, Mo. and FRAMINGHAM, Mass., April 27, 2021 /PRNewswire/ Eurofins Viracor, one of the largest and most recognized infectious diseases testing laboratories in the United States, and Transplant Genomics, the trusted global partner in precision biomarkers for the transplant community innovating to improve patient outcomes, announce that the New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) has approved the Viracor TRAC™ (Transplant Allograft Rejection Check) donor-derived cell-free DNA test and TruGraf® blood gene expression test, both of which help healthcare providers assess rejection status in kidney transplant recipients.
Eurofins Transplant Diagnostics Group Receives New York State CLEP Approval for Novel Rejection Biomarker Assays
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Global Human Gene Sequencing Market Report 2021-2025: COVID-19 Pandemic has Put the Market on Pause
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
ResearchAndMarkets.com s offering.
The market has just gotten started with a handful of small startup companies. Expect the big players to start taking notice.
CRISPR is not just about changing genes. CRISPR identifies unique genetic material instantly, accurately and cheaply. A whole new world of identification and diagnostics opens up. Find out exactly what kind of cold or flu you have. Find out exactly what kind of fish you are eating. Instantly detect the presence of unwelcome bacteria, anywhere. A new COVID test is already available.
Will this disruptive technology change the world of In Vitro Diagnostics? What is the impact on Clinical Laboratories? How will social norms be affected?